The rationale behind this combination originated from the observation that proteasome inhibition with bortezomib elevated the levels of VEGF in GBM stem-like cells [26]; therefore, supplementation with bevacizumab was hypothesized to ameliorate this particular undesirable marizomib effect. Here, VEGFA is linked to glioblastoma.